The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism (Centrin)
Diabetes
About this trial
This is an interventional treatment trial for Diabetes focused on measuring central insulin, insulin resistance, energy metabolism
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 30 and ≤ 70 years
- balanced gender ratio (50: 50)
- BMI 20-25 kg/m² (normal weight subjects)
- BMI 25-35 kg/m² (obese subjects)
Exclusion Criteria:
- acute illness within the last 2 weeks before the examination
- autoimmune diseases and disorders immune- compromised (leukocytes <5000/μl)
- renal insufficiency (creatinine> 1.5 mg / dl)
- heart disease, condition after heart attack
- anemia (Hb <12 g / l, controls at each examination), blood donation within 4 weeks before the examination
- participation in another study within 2 months before the examination
- wear a metal or magnetic objects on or in the body
- claustrophobia
- use of immunomodulatory drugs (cortisol, antihistamines, aspirin)
- thyroid disease
- taking glitazones and insulin therapy
- pregnancy, lactation, menstruation
- cigarette smoking, use of alcohol or drugs, psychiatric disorders
- risk for / or manifest AIDS (HIV) or hepatitis B or C
- liver disease is not attributed to the existence of a non-alcoholic steatosis
- night shift work or circumstances, which do not allow the normal day-night rhythm
- bleeding disorders or disorders in wound healing
- hypersensitivity to local anesthetics
- malignant cancer
- heart rhythm disorders
- polyneuropathy
Sites / Locations
- German Diabetic Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Placebo Comparator
Experimental
Experimental
Placebo Comparator
intranasal insulin in patients
intransal insulin in study participants
placebo in patients
placebo in study participants
taNVS
Sham stimulation
intranasal insulin is applied to diabetic patients under fasting conditions
intranasal insulin is applied to healthy patients under fasting conditions
placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
placebo spray is applied intranasally in healthy participants under fasting conditions
Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
Sham stimulation in the ear lobe is applied for 14 min in healthy participants